Physician profile
William Nester
NPI 1417360967
$5,440.63
in general payments reported to CMS, 2019-2025
31 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $175 · 2021: $148 · 2022: $710 · 2023: $1,135 · 2024: $1,192 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639 · Travel and Lodging: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.73 |
| Travel and Lodging | $769.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,709.50 | 2021-2025 | Onyx Frontier, Symplicity G3, Complete Se Vascular |
| Boston Scientific Corporation | $956.38 | 2022-2025 | Watchman Flx, Watchman Access System, General - Atherectomy |
| Abiomed | $414.89 | 2022-2025 | Impella |
| Abbott Laboratories | $401.39 | 2022-2025 | Cardiomems, Amplatzer Amulet, Xience Skypoint |
| Shockwave Medical, INC | $351.34 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $281.25 | 2022-2025 | |
| Edwards Lifesciences Corporation | $257.37 | 2023-2025 | Hemosphere, Pascal, Mitris Resilia Mitral Valve |
| Heartflow, INC. | $172.67 | 2025 | |
| Acist Medical Systems, INC. | $142.80 | 2023-2024 | |
| Medtronic Vascular, INC. | $140.24 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $75.73 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $68.97 | 2022-2023 | |
| Cardiva Medical, INC. | $58.67 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Atricure, INC. | $45.94 | 2023-2024 | |
| Penumbra, INC. | $43.05 | 2024 | Indigo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.52 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $36.58 | 2022 | |
| Philips North America LLC | $34.57 | 2020 | |
| Siemens Medical Solutions USA, INC. | $26.82 | 2023 | |
| Daiichi Sankyo INC. | $21.79 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $20.55 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.41 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.00 | 2024 | Wainua |
| Scpharmaceuticals INC. | $15.29 | 2023 | |
| Merck Sharp & Dohme LLC | $13.85 | 2023 | Verquvo |
| Amarin Pharma, INC. | $13.78 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $13.43 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $13.26 | 2023 | Xarelto |
| Conetic Solutions, INC. | $12.75 | 2023 | |
| Amgen INC. | $11.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.